NOVO-B:CPH
Novo Nordisk A/S
259,60 DKK
arrow_downward
-1,46%(-3,85) 1D
16-окт., 17:00:00 GMT+2 · DKK
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for NOVO-B...
Open
261,00 DKK
High
262,15 DKK
Low
259,35 DKK
Mkt. cap
893,13 млд
Avg. vol.
5,23 млн
Volume
5,27 млн
52-wk high
409,95 DKK
52-wk low
224,25 DKK
Shares outstanding
3,39 млд
No. of employees
67 миң
Open
261,00 DKK
High
262,15 DKK
Low
259,35 DKK
Mkt. cap
893,13 млд
Avg. vol.
5,23 млн
Volume
5,27 млн
52-wk high
409,95 DKK
52-wk low
224,25 DKK
Shares outstanding
3,39 млд
No. of employees
67 миң
News stories
From web sources and news partners
The Motley Fool
·
9 саат мурун
Novo Nordisk and Eli Lilly Just Got Some Fantastic News
ad-hoc-news.de
·
10 саат мурун
Novo-Nordisk stock: Citi cuts target for Novo-Nordisk stock to DKK 296
Traders Union
·
18 саат мурун
Novo Nordisk shares technical analysis: Buyer support underpins upward price move
Foreign Policy Journal
·
1 күн мурун
Novo Nordisk (NYSE: NVO) Stock Price May Be 63% Undervalued As Buyback And Pipeline Catalysts Mount
Profile
Novo Nordisk A/S, doing business as Novo, is a Danish multinational pharmaceutical company. Novo manufactures and markets pharmaceutical products and services, primarily diabetes and obesity medications and devices. The corporation was created in 1989, through a merger of two Danish pharmaceutical companies, which date back to the 1920s.
Novo employs approximately 68,800 people in 80 countries, and markets its products in approximately 170 countries. Novo is controlled by majority shareholder Novo Holdings which holds 28% of its shares and a majority of its voting shares.
Novo is a full member of the European Federation of Pharmaceutical Industries and Associations.
The company was ranked 25th among Fortune's 100 Best Companies to Work For in 2010, and subsequently ranked 72nd in 2014 and 73rd in 2017. In January 2012, Novo was named the most sustainable company in the world by the business magazine Corporate Knights. It is a leader in the FTSE4Good Index, and the only European company in the top ten.
Novo is the largest pharmaceutical company in Denmark. In 2023, Novo's market capitalization exceeded the GDP of Denmark, and it became the highest valued company in Europe. Wikipedia
About Novo Nordisk A/S
CEOMaziar Mike Doustdar
Employees66,7 миң
Founded1923
HeadquartersBagsværd, Capital Region of Denmark, Дания
SectorPharmaceutical industry
Websitenovonordisk.com